Moderna expands Its mRNA pipeline with new development programs
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Subscribe To Our Newsletter & Stay Updated